Dogma Biotech

Dogma Biotech is a biotechnology company developing AI-designed glycan engineering technologies to advance central nervous system therapeutics. The company's platform decodes the uncharted space of glycomics — mapping and designing new glycan architectures that nature never evolved — and converts the stochastic glycosylation manufacturing process into a fully tunable, cell-based modular biomanufacturing system. Dogma's lead program targets Tay-Sachs disease, a fatal infant neurological condition, where their glyco-engineered enzyme achieved 100% full brain coverage, greater than 40% single-dose efficacy in substrate degradation, and 50% neuroprotection in neurodegeneration markers in animal models. The team has collectively contributed to over 3 FDA-approved medicines, 5+ INDs, 10 patents, and 100+ publications. Backed by QB3 and collaborating with world-class institutions, Dogma Biotech is pioneering glycoengineering as a programmable drug design variable for transforming protein therapeutics.